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ABSTRACT In the last decade, Clostridium difficile infection (CDI) has reached an
epidemic state with increasing incidence and severity in both health care and com-
munity settings. Vancomycin is an important first-line therapy for CDI, and the emer-
gence of resistance would have significant clinical consequences. In this study, we
describe for the first time a vanB2 vancomycin resistance operon in C. difficile, iso-
lated from an Australian veal calf at slaughter. The operon was carried on an ~42-kb
element showing significant homology and synteny to Tn1549, a conjugative trans-
poson linked with the emergence and global dissemination of vancomycin-resistant
enterococci (VRE). Notably, the C. difficile strain did not show any reduced suscepti-
bility to vancomycin in vitro (MIC, 1 mg/liter), possibly as a result of an aberrant
vanRB gene. As observed for other anaerobic species of the animal gut microbiota,
C. difficile may be a reservoir of clinically important vancomycin resistance genes.
IMPORTANCE In an era when the development of new antimicrobial drugs is
slow, vancomycin remains the preferred antimicrobial therapy for Clostridium difficile
infection (CDI), the most important health care-related infection in the world today.
The emergence of resistance to vancomycin would have significant consequences in
relation to treating patients with CDI. In this paper, we describe for the first time a
complete set of vancomycin resistance genes in C. difficile. The genes were very sim-
ilar to genes found in vancomycin-resistant enterococci (VRE) that were associated
with the emergence and global dissemination of this organism. Fortunately, the C.
difficile strain did not show any reduced susceptibility to vancomycin in vitro (MIC, 1
mg/liter), possibly because of a small difference in one gene. However, this observa-
tion signals that we may be very close to seeing a fully vancomycin-resistant strain
of C. difficile.
KEYWORDS: antimicrobial resistance, Clostridium difficile infection, mobile genetic
element, vanB
Since its first description as the causative agent of pseudomembranous colitis in1978, Clostridium difficile has emerged as a major enteropathogen of humans and
a significant burden to global health care systems (1). Vancomycin has been a first-line
therapy for C. difficile infection (CDI) for almost 30 years, retaining good activity against
C. difficile, including strains belonging to epidemic lineages and those with increased
resistance to metronidazole (2). Despite sporadic reports of reduced susceptibility to
vancomycin (MIC, 4 mg/liter; CLSI susceptibility breakpoint, 2 mg/liter), to date no
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underlying mechanisms have been identified (2). Sequencing of C. difficile genomes
revealed the widespread presence of a vancomycin resistance operon (vanGCd) (3).
Although it is often referred to as cryptic (phenotypically silent), transcriptional and
biochemical studies showed that vanGCd was functional, conferring a modest increase
in MIC in C. difficile (from 1 mg/liter to 2 mg/liter) (4). Here, we present the first
description of a cryptic vanB2 operon in C. difficile, carried on an ~42-kb element
showing significant homology and synteny to Tn1549, a conjugative transposon (CTn)
linked with the emergence and global dissemination of vancomycin-resistant entero-
cocci.
C. difficile strain AI0499 was recovered from the carcass of a calf (aged 7 days) in
Victoria, Australia, in April 2013, identified as C. difficile by morphological and pheno-
typic traits as previously described (5), and confirmed by matrix-assisted laser desorp-
tion ionization–time of flight (MALDI-TOF) mass spectrometry. By PCR ribotyping, strain
AI0499 was identified as ribotype (RT) 033 and thus negative for genes encoding large
clostridial toxins A and B (tcdA tcdB) but positive for genes encoding binary toxin
(cdtA cdtB) (5).
Whole-genome sequencing (WGS) of AI0499 was performed in duplicate at two
independent institutions. Genomic DNA (gDNA) was extracted using a Gentra Puregene
kit (Qiagen, Hilden, Germany), and libraries were created using Nextera XT protocols
(Illumina, Inc., San Diego, CA). The first sequence run was performed on an Illumina
MiSeq sequencer with 250-bp paired-end (PE) chemistry, generating 406,204 reads and
36 coverage. The second was performed on an Illumina HiSeq sequencer with 100-bp
PE chemistry, generating 3,684,407 reads and 131 coverage. Multilocus sequence
typing (MLST) and antimicrobial gene profiling were performed using SRST2 (6).
Genomes were assembled, annotated, and curated using a pipeline comprising SPAdes,
Prokka, Artemis, and Easyfig (7–10). In vitro susceptibility to vancomycin was investi-
gated in triplicate using the CLSI agar dilution methodology as previously described
(11) and in triplicate using Etest methodology.
WGS and de novo assembly of the AI0499 genome revealed a single chromosome of
4,095,918 bp and 28.75% GC with 3,960 coding sequences (CDS) and an overall
coverage of ~130. Strain AI0499 was characterized as sequence type (ST) 11 (MLST
clade 5) and harbored a complete binary toxin locus comprising cdtR, cdtA, and cdtB
genes. Strain AI0499 possessed an uncommon pathogenicity locus identified as toxi-
notype XI and defined by the complete absence of tcdB, a fragmented and truncated
tcdA gene (A2 fragment, 3,231 bp; A3 fragment, 915 bp), and a variant tcdC gene (allele
tcdC-A1 as described by Curry et al.) (12, 13). SRST2 identified seven vancomycin
resistance genes with 99% sequence identity to vanXB, vanB, vanHB, vanW, vanYB,
vanSB, and vanRB. AI0499 was negative for vanGCd.
In Gram-positive bacteria, vancomycin resistance is mediated by several van oper-
ons and arises as a result of both (i) biosynthesis of modified peptidoglycan precursors
ending in D-Ala-D-Lac or D-Ala-D-Ser to which vancomycin shows reduced binding and
(ii) the elimination of high-affinity natural D-Ala-D-Ala precursors (13). Tn1549 (GenBank
accession no. AF192329) is a member of the Tn916 family of conjugative transposons
and harbors a vanB subtype 2 operon (vanB2) comprising genes encoding a dipepti-
dase (vanXB, 609 bp), a ligase (vanB, 1,029 bp), a dehydrogenase (vanHB, 972 bp), a
putative hydrolase (vanW, 828 bp), and a carboxypeptidase (vanYB, 807 bp). Two
further genes, vanSB (1,344 bp) and vanRB (663 bp), also colocated within the vanB2
operon, play a crucial role in the phenotypic expression of vancomycin resistance (14).
Sequence analysis of regions flanking the vanB2 gene cluster in AI0499 revealed an
element of 42,375 bp showing significant sequence identity and synteny with the
prototypical Tn1549 (GenBank sequence accession no. AF192329) (Fig. 1). Notably, this
element differed markedly, particularly in its accessory region, from other putative
Tn1549-like CTns, CTn2, CTn4, and CTn5, previously described in C. difficile (data not
shown) (15, 16).
The element designated Tn1549-like contained 38 open reading frames (ORFs) and,
like Tn1549, was organized into transposition, accessory (antimicrobial resistance), and
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conjugation regions (Fig. 1). Defining the left and right terminal ends of the element
were 11-bp inverted repeats matching those found in Tn1549 and likely representing
excision/integration sites (14). Comparing the vanB2 operon in AI0499 to that of Tn1549
revealed significant homology in vanXB, vanB, vanHB, vanW, vanYB, and vanSB (Fig. 1).
However, in AI0499 vanRB was fragmented into a 525-bp fragment located adjacent to
vanSB and a 134-bp fragment some 2.1 kb away (Fig. 1). Notably, two CDS present in
strain AI0499 but absent in Tn1549 were found interrupting the vanRB gene. Bm3R1
(582 bp) and KU558763_7 (1,032 bp) encode a transcriptional repressor and decarbox-
ylase originating from Bacillus megaterium and Bacillus cereus, respectively. The Tn1549-
like element contained four additional CDS completely absent from Tn1549 (Fig. 1).
KU558763_5 (684 bp) and KU558763_6 (702 bp), colocated between the transposition
and vancomycin resistance regions, encode hypothetical proteins originating from
Clostridium clostridioforme. KU558763_10 (1,803 bp), located ~3 kb into the conjugation
region, and KU558763_25 (1,665 bp), located near the far left extremity, both encode
group II introns originating from an unidentified Clostridiales member and C. clostrid-
ioforme, respectively.
Several clostridial species, including C. bolteae, C. hathewayi, C. innocuum, C. clos-
tridioforme, and C. symbiosum, harbor vanB-like elements and demonstrate vancomycin
resistance in vitro (17–19). Notably, strain AI0499 did not show any reduced suscepti-
bility to vancomycin in vitro (MIC, 1 mg/liter), most likely due to the fragmentation of
vanRB; however, this first description of a phenotypically silent vanB2 operon in
C. difficile further confirms that anaerobes of the animal gut microbiota are a reservoir
of clinically important vanB-like resistance operons.
FIG 1 Comparative genomic analysis of Tn1549-like element in C. difficile strain AI0499 and prototypical Tn1549 of Enterococcus faecalis
(GenBank accession no. AF192329). Arrows indicate open reading frames (ORFs) and direction of transcription. Excisionase (xis) and
integrase (int) genes are shown in yellow, and genes comprising the vanB2 operon (vanXB, vanB, vanHB, vanW, vanYB, vanSB, and vanRB)
are shown in green, with the remaining ORFs shown in blue. The figure was prepared using Easyfig (minimum blast hit length of 100 bp
and a maximum E value of 0.001) (10). Vertical blocks between sequences indicate regions of homology with Blast nucleotide identity shown
on a colored scale ranging from 70% (light gray) to 100% (dark gray). Bm3R1 and ORFs KU558763_5, KU558763_6, KU558763_7,
KU558763_10, and KU558763_25 are shown to be present in strain AI0499 but absent from the sequence with accession no. AF192329 with
Bm3R1 and KU558763_7 interrupting vanRB (vanRB_1 and vanRB_2 fragments shown). Overall sizes of elements in strain AI0499 and the
sequence with accession no. AF192329 are 42,375 bp and 33,805 bp, respectively.
vanB2 Element in C. difficile
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Accession number(s).The nucleotide sequence of the Tn1549-like element from
strain AI0499 has been submitted to GenBank (accession no. KU558763). The HiSeq PE
sequence reads have been deposited in the NCBI Short Read Archive under accession
no. SRP067713.
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